More about

Secondary Progressive Multiple Sclerosis

Clinical Guidance
Multiple Sclerosis
Assessment and Treatment

Treatment Options

Pavan Bhargava, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Multiple Sclerosis
Assessment and Treatment

Assessment of Multiple Sclerosis

Pavan Bhargava, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Multiple Sclerosis
Overview

Pathophysiology

Pavan Bhargava, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Multiple Sclerosis
Overview

Etiology and Risk Factors

Pavan Bhargava, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Multiple Sclerosis
Overview

Definition and Classification

Pavan Bhargava, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

CME
Video

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations
0.75 CME
0.75 CNE
45 MINS
$0 FEE
CME
Ace the Case

Ace the Case: A 52-Year-Old Woman With Gradual Walking Difficulties

Ace the Case: A 52-Year-Old Woman With Gradual Walking Difficulties
0.25 CME
0.25 CNE
15 MINS
$0 FEE
CME
Ace the Case

Ace the Case: A 32-Year-Old Woman With Aphasia and Hemiparesis

Ace the Case: A 32-Year-Old Woman With Aphasia and Hemiparesis
0.25 CME
0.25 CNE
15 MINS
$0 FEE
News
July 06, 2021
2 min read
Save

High-efficacy therapy 'superior' in reducing relapses, but not delaying disability, in MS

Patients with active secondary progressive MS who received high-efficacy therapy experienced relapses less often than those on low-efficacy therapy, according to findings published in Neurology.

News
October 27, 2020
3 min read
Save

Outcome measures in MS trials require more research ‘to improve clinical trial design’

Outcome measures in MS trials require more research ‘to improve clinical trial design’

The timed 25-foot walk test and the nine-hole peg test demonstrated lower rates of improvement than the Expanded Disability Scale Status, which is consistent with less measurement error, according to findings published in Neurology.

View more